ZBH Financials Zimmer Biomet

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Aug 9, 2026, 10:16 UTC Overview →

Growth & profitability

Revenue has grown 6.1% per year over the past 5 years.
Operating margin has expanded, at 13.3% in the latest year.
Free cash flow has grown 6.2% per year over the past 5 years.

Financial health

Total debt ($7.5B) exceeds cash ($592M); net debt is $6.9B.
Total debt has grown slower than revenue (-1.5% vs 6.1% per year).
Total debt is 3.4× EBITDA.

Shareholder returns

Dividends have been paid for 14 consecutive years, consuming 27.0% of earnings and 12.9% of free cash flow.
The dividend has declined 0.8% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
2025	$8.2B	$705M	69.7%	13.3%	5.6%	3.1%	$1.5B	$7.5B	$592M
2024	$7.7B	$904M	71.5%	16.7%	7.2%	4.2%	$1.3B	$6.2B	$526M
2023	$7.4B	$1.0B	71.8%	17.3%	8.2%	4.8%	$1.3B	$5.8B	$416M
2022	$6.9B	$231M	70.9%	10.0%	1.9%	1.1%	—	$5.7B	$376M
2021	$6.8B	$402M	71.3%	12.6%	3.2%	1.7%	$1.4B	$7.1B	$378M
2020	$6.1B	-$139M	70.2%	1.4%	-1.1%	-0.6%	$1.1B	$8.1B	$775M
2019	$7.0B	$1.1B	72.1%	16.0%	9.1%	4.6%	$1.4B	$8.2B	$618M
2018	$7.9B	-$379M	71.4%	0.4%	-3.4%	-1.6%	$1.6B	$8.9B	$543M
2017	$7.8B	$1.8B	72.7%	10.2%	15.5%	7.0%	$1.4B	$10.1B	$524M
2016	$7.7B	$306M	68.9%	10.7%	3.2%	1.1%	$1.4B	$11.2B	$634M
2015	—	$147M	—	—	1.5%	0.5%	—	$11.5B	$1.5B
2014	—	$720M	—	—	11.0%	7.5%	—	$1.4B	$1.1B
2013	—	$780M	—	—	12.4%	8.1%	$863M	$1.7B	$1.1B
2012	—	$755M	—	—	12.9%	8.4%	$1.0B	$1.8B	$884M
2011	—	$761M	—	—	13.8%	8.9%	$1.1B	$1.7B	$768M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
Jun '26	$2.2B	$198M	70.8%	15.0%	1.6%	0.9%	$394M	$7.5B	$410M
Mar '26	$2.1B	$238M	72.4%	17.9%	1.9%	1.0%	$323M	$7.5B	$424M
Dec '25	$2.2B	$139M	64.7%	6.9%	1.1%	0.6%	$443M	$7.5B	$592M
Sep '25	$2.0B	$231M	72.1%	17.6%	1.8%	1.0%	$364M	$8.1B	$1.3B
Jun '25	$2.1B	$153M	71.5%	14.4%	1.2%	0.7%	$328M	$7.6B	$557M
Mar '25	$1.9B	$182M	71.2%	15.3%	1.5%	0.8%	$338M	$7.2B	$1.4B
Dec '24	$2.0B	$240M	71.0%	19.2%	1.9%	1.1%	$455M	$6.2B	$526M
Sep '24	$1.8B	$249M	70.5%	15.3%	2.0%	1.1%	$351M	$6.5B	$569M
Jun '24	$1.9B	$243M	71.5%	18.1%	1.9%	1.1%	$317M	$5.8B	$420M
Mar '24	$1.9B	$172M	72.9%	14.1%	1.4%	0.8%	$173M	$5.8B	$393M
Dec '23	$1.9B	$419M	72.2%	18.3%	3.4%	2.0%	—	$5.8B	$416M
Sep '23	$1.8B	$163M	70.4%	15.2%	1.3%	0.8%	$253M	$5.5B	$292M
Jun '23	$1.9B	$210M	71.9%	17.6%	1.7%	1.0%	$251M	$5.7B	$320M
Mar '23	$1.8B	$233M	72.6%	17.9%	1.9%	1.1%	$261M	$5.8B	$330M
Dec '22	$1.8B	-$131M	71.5%	-1.6%	-1.1%	-0.6%	—	$5.7B	$376M
Sep '22	$1.7B	$194M	70.8%	14.7%	1.6%	0.9%	—	$5.7B	$545M
Jun '22	$1.8B	$154M	71.3%	15.8%	1.3%	0.7%	—	$6.0B	$386M
Mar '22	$1.7B	$14M	69.9%	11.9%	0.1%	0.1%	—	$6.3B	$436M
Dec '21	$1.8B	-$84M	69.8%	7.5%	-0.7%	-0.4%	$317M	$7.1B	$378M
Sep '21	$1.7B	$146M	70.8%	14.4%	1.1%	0.6%	$389M	$7.5B	$920M

Valuation over time

How the market has priced ZBH against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has fallen from 106.4× (Mar '23) to 26.3× (Nov '26).
The price-to-sales ratio has fallen from 3.5× (Mar '23) to 2.3× (Nov '26).
The dividend yield has risen from 0.8% (Mar '23) to 1.0% (Nov '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is ZBH growing its revenue and profit?

Over the past 5 years, Zimmer Biomet's revenue has grown 6.1% per year. These are computed facts, not advice.

How much debt does ZBH have?

As of FY2025, Zimmer Biomet reported $7.5B of total debt against $592M of cash.

What is ZBH's profit margin?

In FY2025, gross margin was 69.7%, operating margin 13.3%, and net margin 8.6%.

What is ZBH's P/E ratio?

Zimmer Biomet's P/E (TTM) is 23.01 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the ZBH stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 26.3× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.